Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism

Tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 have turned chronic myeloid leukaemia (CML) from a fatal disease into a manageable condition for most patients. Despite improved survival, targeting drug‐resistant leukaemia stem cells (LSCs) remains a challenge for curative CML therapy. Aberrant...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, Mayra A., Olivas, Idaly M., Bencomo‐Alvarez, Alfonso E., Rubio, Andres J., Barreto‐Vargas, Christian, Lopez, Jose L., Dang, Sara K., Solecki, Jonathan P., McCall, Emily, Astudillo, Gonzalo, Velazquez, Vanessa V., Schenkel, Katherine, Reffell, Kelaiah, Perkins, Mariah, Nguyen, Nhu, Apaflo, Jehu N., Alvidrez, Efren, Young, James E., Lara, Joshua J., Yan, Dongqing, Senina, Anna, Ahmann, Jonathan, Varley, Katherine E., Mason, Clinton C., Eide, Christopher A., Druker, Brian J., Nurunnabi, Md, Padilla, Osvaldo, Bajpeyi, Sudip, Eiring, Anna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763536/
https://www.ncbi.nlm.nih.gov/pubmed/36536477
http://dx.doi.org/10.1002/ctm2.1146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763536/
https://www.ncbi.nlm.nih.gov/pubmed/36536477
http://dx.doi.org/10.1002/ctm2.1146

Ejemplares similares